Vigil Neuroscience reports Interim Data from Phase 2 Clinical Trial

Vigil Neuroscience presented their findings from 6 patients during the first 6 months of the Phase 2 Ignite proof-of-concept clinical trial. The data is promising, and Vigil is setting the stage for advancements in ALSP by providing insights from the first Natural History Study and Clinical Trial for ALSP. Congratulations to the team at Vigil Neuroscience and to the ALSP Community!

Read the full press release: Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE — Vigil Neuroscience, Inc